XML 45 R33.htm IDEA: XBRL DOCUMENT v3.20.2
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)
 1 Months Ended 3 Months Ended 9 Months Ended 41 Months Ended 81 Months Ended
Jul. 27, 2020
USD ($)
Apr. 05, 2018
USD ($)
Oct. 30, 2020
USD ($)
Sep. 30, 2020
USD ($)
milestone
Aug. 31, 2020
USD ($)
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
$ / shares
Feb. 29, 2020
USD ($)
product_target
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Aug. 31, 2019
USD ($)
May 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
May 31, 2017
USD ($)
Jan. 31, 2014
USD ($)
program
Sep. 30, 2020
USD ($)
milestone
product_target
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
milestone
option
product
$ / shares
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
milestone
Sep. 30, 2020
USD ($)
product
milestone
Feb. 28, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 $ 57,763,000 $ 21,958,000 $ 92,392,000 $ 47,577,000      
Maximum number of product targets replaced | product_target                                 10            
Recognized portion of equity issued                                   7,000   $ 25,000      
Revenue reduction due to decrease in measure of proportional cumulative performance, percentage                                       38.00%      
Other long-term liabilities       $ 6,238,000           $ 5,711,000             $ 6,238,000   6,238,000   $ 6,238,000 $ 6,238,000  
California Institute For Regenerative Medicine Agreement                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Funds due under the agreement                         $ 8,000,000.0                    
Other long-term liabilities       6,200,000           5,700,000             6,200,000   6,200,000   6,200,000 6,200,000  
California Institute For Regenerative Medicine Agreement | Research Grants                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                     5,200,000        
Novartis | Collaboration and License Agreement                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Proceeds from collaborators         $ 75,000,000.0                                    
Collaborative arrangement transaction price $ 95,100,000                                            
License fee 75,000,000.0                                            
Collaborative arrangement estimated reimbursable service costs 20,100,000                                            
Deferred revenue       75,000,000.0                         75,000,000.0   75,000,000.0   75,000,000.0 75,000,000.0  
Revenues                                 0   0        
Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value       1,500,000                         $ 1,500,000   1,500,000   1,500,000 1,500,000  
Percent of initial recognition                                 2.00%            
Novartis | Collaboration and License Agreement | Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones | Maximum                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received 420,000,000.0                                            
Novartis | Collaboration and License Agreement | Achievement of Commercial Milestones | Maximum                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received $ 300,000,000.0                                            
Biogen MA, Inc.                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 $ 9,621,000 0 17,799,000 $ 0      
Biogen MA, Inc. | Collaboration Agreements                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 7,306,000 0 14,050,000 0      
Biogen MA, Inc. | Collaboration and License Agreement                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Proceeds from collaborators           $ 125,000,000.0     $ 125,000,000.0                            
Maximum milestone payment receivable                 $ 2,370,000,000                            
Number of product targets | product_target                 12                            
Number of product targets selected | product_target                 3                            
Number of additional product targets | product_target                 9                            
Target selection period                 5 years                            
Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value       7,000,000.0                         $ 7,000,000.0   $ 7,000,000.0   7,000,000.0 7,000,000.0  
Percent of initial recognition                                 2.00%   2.00%        
Portion of contract asset recognized       4,100,000                         $ 4,100,000   $ 4,100,000   4,100,000 4,100,000  
Amortization                                 100,000   300,000        
Biogen MA, Inc. | Collaboration and License Agreement | Maximum                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Research period                 7 years                            
Biogen MA, Inc. | Collaboration and License Agreement | Pre-approval Milestone                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Maximum milestone payment receivable                 $ 925,000,000.0                            
Biogen MA, Inc. | Collaboration and License Agreement | Sales-based Milestone                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Maximum milestone payment receivable                 $ 1,450,000,000                            
Biogen MA, Inc. | Stock Purchase Agreement                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Deferred revenue       190,500,000                         190,500,000   190,500,000   190,500,000 190,500,000  
Number of shares issued in transaction (in shares) | shares             24,420,157                                
Sale of stock, price per share (in dollars per share) | $ / shares             $ 9.2137                                
Consideration received on transaction             $ 225,000,000.0                                
Standstill restriction period                 3 years                            
Standstill restriction, ownership threshold percentage ownership percentage                                             5.00%
Agreement restriction, percentage of shares held                                             50.00%
Voting provisions expiration period                 2 years                            
Voting provisions, ownership threshold percentage                                             5.00%
Excess consideration received on transaction                                     79,600,000        
Recognized portion of equity issued                                 2,900,000            
Collaboration agreement, equity issued       145,400,000                         145,400,000   145,400,000   145,400,000 145,400,000  
Kite Pharma Inc                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 7,294,000 8,861,000 21,935,000 26,233,000      
Kite Pharma Inc | Collaboration Agreements                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 6,296,000 6,296,000 18,750,000 18,682,000      
Kite Pharma Inc | Collaboration and License Agreement                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Collaborative arrangement transaction price   $ 189,300,000                                          
Collaborative arrangement estimated reimbursable service costs   39,300,000                                          
Deferred revenue       87,700,000           106,500,000             87,700,000   $ 87,700,000   87,700,000 87,700,000  
Milestone payments received   $ 150,000,000.0                                          
Initial research term of agreement   6 years                                          
Number of options to extend initial research term | option                                     2        
Extended research term of agreement                                     1 year        
Separate upfront fee   $ 10,000,000.0                                          
Collaborative arrangement estimated reimbursable service costs for new research plan                     $ 3,400,000                        
Revenues under agreement   150,000,000.0                                          
Kite Pharma Inc | Collaboration and License Agreement | Maximum                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received   3,010,000,000.00                                          
Kite Pharma Inc | Collaboration and License Agreement | Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Contingent development - and sales-based milestone payments to be received   1,260,000,000                                          
Kite Pharma Inc | Collaboration and License Agreement | Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Contingent development - and sales-based milestone payments to be received   $ 1,750,000,000                                          
Pfizer                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Deferred revenue       700,000           4,000,000.0             700,000   $ 700,000   700,000 700,000  
Revenues                                 9,200,000 468,000 12,985,000 1,538,000      
Milestone payments received                           $ 12,000,000.0                  
Revenues under agreement                   25,000,000.0                 1,200,000        
Contract to perform for others, cumulative compensation earned       24,800,000                         24,800,000   24,800,000   24,800,000 24,800,000  
Revenue reduction due to decrease in measure of proportional cumulative performance                                       3,000,000.0      
Increase (decrease) in revenue               $ 2,400,000                     8,800,000        
Increase (decrease) in net loss               $ 2,400,000                     $ 8,800,000        
Increase (decrease) in basic net loss per share (in dollars per share) | $ / shares               $ (0.02)                     $ 0.07        
Pfizer | Collaboration Agreements                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 4,200,000 468,000 $ 7,985,000 1,538,000      
Pfizer | SB-525 and Other Products                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues under agreement                             $ 70,000,000.0                
Pfizer | C9ORF72                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received       5,000,000.0                                      
Collaborative arrangement transaction price                           17,000,000.0                  
Deferred revenue       $ 0.0           8,000,000.0             0.0   0.0   0.0 0.0  
Milestone payments received                           12,000,000.0                  
Extended research term of agreement       2 years                                      
Revenues under agreement                           5,000,000.0     5,000,000.0   5,000,000.0        
Pfizer | Milestone Achievement                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 5,000,000 0 5,000,000 0      
Pfizer | Maximum | SB-525 and Other Products                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Potential amount to be funded for achievement of specified commercialized and sales milestones                             266,500,000                
Pfizer | Maximum | SB-525                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Milestone revenue receivable                             300,000,000.0                
Pfizer | Maximum | Other Products                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Milestone revenue receivable                             175,000,000.0                
Pfizer | Phase 3 Clinical Trial                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Contract to perform for others, cumulative compensation earned       $ 29,800,000                         29,800,000   29,800,000   29,800,000 $ 29,800,000  
Pfizer | Phase 3 Clinical Trial | Forecast | Subsequent Event                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received     $ 30,000,000.0                                        
Pfizer | Achievement of Specified Clinical Development Intellectual Property and Regulatory Milestones | Maximum | SB-525 and Other Products                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received                             208,500,000                
Pfizer | Achievement of First Commercial Sale Milestones | Maximum | SB-525 and Other Products                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received                             $ 475,000,000.0                
Pfizer | Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones | Maximum | C9ORF72                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received                           60,000,000.0                  
Pfizer | Achievement of Commercial Milestones | Maximum | C9ORF72                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received                           $ 90,000,000.0                  
Pfizer SB-525                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Collaborative arrangement transaction price                                     134,000,000.0        
Revenues                                 30,084,000 3,440,000 $ 33,696,000 5,035,000      
Agreement termination, term                                     15 years        
Revenues under agreement                                     $ 55,000,000.0        
Research Service Fees                                     79,000,000.0        
Pfizer SB-525 | Collaboration Agreements                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 $ 221,000 3,440,000 $ 2,737,000 5,035,000      
Pfizer SB-525 | SB-525 and Other Products                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Milestone payments received                                         $ 55,000,000.0    
Number of milestones achieved | milestone       2                         2   2   2 2  
Number of products approved | product                                     0        
Number of milestones included in transaction price | milestone                                     0        
Pfizer SB-525 | Milestone Achievement                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 $ 29,863,000 0 $ 30,959,000 0      
Pfizer SB-525 | Amended Collaboration And License Agreement                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Deferred revenue       $ 200,000                         200,000   200,000   $ 200,000 $ 200,000  
Pfizer SB-525 | Amended Collaboration And License Agreement | Phase 3 Clinical Trial                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Deferred revenue       200,000                         200,000   200,000   200,000 $ 200,000  
Sanofi                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 1,498,000 2,754,000 $ 3,789,000 7,763,000      
Agreement termination, term                                     180 days        
Revenues under agreement                               $ 20,000,000.0              
Milestone revenue receivable                     6,000,000.0             6,000,000.0   6,000,000.0      
Number of products approved | product                                           0  
Increase (decrease) in revenue                                     $ (2,200,000)        
Increase (decrease) in net loss                                     $ 2,200,000        
Increase (decrease) in basic net loss per share (in dollars per share) | $ / shares                                     $ (0.02)        
Number of research programs | program                               2              
Sanofi | Collaboration Agreements                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 321,000 940,000 $ (28,000) 2,594,000      
Sanofi | Milestone Achievement                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Revenues                                 216,000 0 (19,000) 0      
Sanofi | Collaboration and License Agreement                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Collaborative arrangement transaction price                               $ 93,300,000              
Collaborative arrangement estimated reimbursable service costs                               59,800,000              
Deferred revenue       1,700,000           $ 1,700,000             1,700,000   1,700,000   1,700,000 $ 1,700,000  
Revenues under agreement                               20,000,000.0              
Number of milestones included in transaction price | milestone                                           0  
Cumulative milestone achieved       7,100,000                         7,100,000   7,100,000   7,100,000 $ 7,100,000  
Sanofi | Collaboration and License Agreement | Maximum                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received                               276,300,000              
Sanofi | Collaboration and License Agreement | Milestone Two                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Milestone revenue receivable                     $ 7,500,000             $ 7,500,000   $ 7,500,000      
Sanofi | Collaboration and License Agreement | Milestone Three                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Milestone revenue receivable       13,500,000                         13,500,000   13,500,000   13,500,000 13,500,000  
Sanofi | Collaboration and License Agreement | ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Milestone payments received                       $ 6,000,000.0                      
Cumulative milestone achieved       $ 5,700,000                         $ 5,700,000   $ 5,700,000   $ 5,700,000 $ 5,700,000  
Sanofi | Collaboration and License Agreement | Achievement Of Specified Clinical Development And Regulatory Milestones | Maximum                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received                               115,800,000              
Sanofi | Collaboration and License Agreement | Achievement of Specified Sales Milestones | Maximum                                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                              
Development and sales-based milestone payments to be received                               $ 160,500,000